MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment.
- MinervaX provides clinical and leadership update 07/10/2021
- MinervaX announces completion of 47.4 mEUR financing 15/12/2020
- MinervaX announces investment of 4.4 mEUR 21/01/2019
- MinervaX announces results from Phase I clinical trial 05/01/2017
- Innovation Foundation Grant 19/09/2016